Dopamine receptor subtypes contribution to Homer1a induction: insights into antipsychotic molecular action

Felice Iasevoli1, Carmine Tomasetti, Alberto Ambesi-Impiombato

  • 1Laboratory of Molecular Psychiatry and Psychopharmacotherapeutics, Section of Psychiatry, Department of Neurosciences, University School of Medicine Federico II, Via Pansini 5, 80131 Naples, Italy.

Insights

Dopamine receptor antagonists differentially regulate Homer1a gene expression in brain regions implicated in schizophrenia. This study clarifies the specific roles of dopamine receptors in Homer1a induction and related gene expression.

Area of Science:

  • Neuroscience
  • Molecular Psychiatry
  • Genetics

Background:

  • Homer1a is a candidate gene for schizophrenia.
  • Dopamine receptor antagonists used in schizophrenia treatment induce Homer1a expression, but receptor-specific roles are unclear.

Purpose of the Study:

  • To investigate Homer1a gene expression induced by selective dopamine receptor antagonists.
  • To evaluate the expression of related genes mGluR5 and Homer1b.
  • To analyze gene expression in brain regions relevant to schizophrenia (striatum, cortex, hippocampus).

Main Methods:

  • Administered selective dopamine receptor antagonists (D1, D2, D3, D4), haloperidol, and terguride to rodents.
  • Analyzed Homer1a, Homer1b, and mGluR5 gene expression in specific brain regions using quantitative methods.
  • Correlated gene expression changes with specific dopamine receptor antagonism.

Main Results:

  • Homer1a induction varied across dopamine receptors and brain regions (striatum, cortex).
  • Dopamine receptor antagonists differentially affected Homer1b and mGluR5 expression in striatum, cortex, and hippocampus.
  • Specific antagonists showed distinct patterns of gene regulation, suggesting differential control by dopamine receptor subtypes.

Conclusions:

  • Dopamine receptor antagonism differentially regulates Homer1a, Homer1b, and mGluR5 gene expression.
  • Findings highlight the complex interplay between dopamine receptor subtypes and gene expression relevant to schizophrenia pathophysiology.
  • This research provides insights into the molecular mechanisms underlying antipsychotic drug action.

Related Concept Videos

Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Antipsychotic Drugs: Therapeutic Uses and Side Effects01:21

Antipsychotic Drugs: Therapeutic Uses and Side Effects

Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...